💨 Abstract

Voyager Therapeutics Inc. reported a loss of $31 million in Q1 2025, with a per-share loss of 53 cents. The results were below Wall Street expectations for a loss of 35 cents per share and revenue of $19.2 million, with actual revenue at $6.5 million. The gene therapy company's stock report can be accessed at https://www.zacks.com/ap/VYG

Courtesy: wtop.com